|
 |
| Heerlen,NL,28-Apr-2004 |
|
|
- Sales up 29% from Q1 2003, mainly because of contribution from DSM Nutritional Products and autonomous volume growth of 5%
- Operating profit 21% higher than in Q1 2003; net profit up 8% from Q1 2003
- Development of DSM Nutritional Products above expectations
- DSM Anti-Infectives puts results of Life Science Products under strong pressure
- Q2 operating profit expected to be around Q1 2004 level; profit on ordinary activities after taxation for 2004 expected to be clearly higher than that for 2003
|
|
|
|
|
